Researchers have uncovered the role of calcium and how it interacts with alpha-synuclein in the development of Parkinson’s disease.
A new study from TauRx reports success in reversing symptoms of Parkinson’s disease in mouse models treated with LTMX.
A recent study reported deposits of a protein, alpha-synuclein, in the synapses of dementia with Lewy bodies patients. The researchers believe it may be this protein that is responsible for the dementia symptoms and the progression of DLB in the brain.
Researchers have found the first evidence that autoimmunity plays a role in Parkinson’s disease, showing that T cells recognize α-synuclein peptides.
Researchers from the University of Central Florida hope to use the CRISPR Cas9 method to screen drugs for Parkinson’s disease.
The Systemic Synuclein Sampling Study (S4) is uniquely designed to identify a reproducible diagnostic and progression biomarker for Parkinson’s disease.
In the quest to cross the BBB, researchers have developed immunoliposomes targeted to BBB receptors and α-synuclein that could potentially enable the transport of drugs to reach one of the drug targets in Parkinson’s disease.
New research has demonstrated that a naturally occurring compound, squalamine, may prevent the formation of the α-synuclein aggregates that are characteristic of Parkinson’s disease onset.
Scientists have developed a method of detecting a molecule linked to Parkinson’s disease in samples of spinal fluid taken from patients, a step that could one day help to improve early diagnosis of the disease.
A novel model recreates the early spread of Parkinson’s disease in the brain to provide scientists with an inside look of where the disease starts, and potentially find methods to halt its progression.